vs
缤客控股（BKNG）与赛默飞世尔科技（TMO）财务数据对比。点击上方公司名可切换其他公司
赛默飞世尔科技的季度营收约是缤客控股的1.7倍（$11.0B vs $6.3B），缤客控股同比增速更快（16.0% vs 6.2%），缤客控股自由现金流更多（$1.4B vs $825.0M），过去两年缤客控股的营收复合增速更高（19.9% vs 2.2%）
缤客控股是全球领先的旅行服务集团，旗下运营Booking.com、Priceline、Agoda、Kayak等知名在线平台，为休闲及商务旅客提供酒店预订、机票订购、租车服务、度假套餐、餐厅预约等服务，业务覆盖全球绝大多数国家和地区，合作数百万家旅游及餐饮商户。
赛默飞世尔科技是美国知名生命科学与临床研究企业，总部位于马萨诸塞州沃尔瑟姆，2006年由热电公司与飞世尔科技合并组建，为全球客户提供分析仪器、临床开发解决方案、特色诊断产品及实验室、制药、生物技术领域专业服务。
BKNG vs TMO — 直观对比
营收规模更大
TMO
是对方的1.7倍
$6.3B
营收增速更快
BKNG
高出9.9%
6.2%
自由现金流更多
BKNG
多$592.0M
$825.0M
两年增速更快
BKNG
近两年复合增速
2.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $6.3B | $11.0B |
| 净利润 | — | $1.7B |
| 毛利率 | — | — |
| 营业利润率 | 32.0% | 16.9% |
| 净利率 | — | 15.0% |
| 营收同比 | 16.0% | 6.2% |
| 净利润同比 | — | 9.6% |
| 每股收益（稀释后） | $43.66 | $4.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BKNGTMO
| Q1 26 | — | $11.0B | ||
| Q4 25 | $6.3B | $12.2B | ||
| Q3 25 | $9.0B | $11.1B | ||
| Q2 25 | $6.8B | $10.9B | ||
| Q1 25 | $4.8B | $10.4B | ||
| Q4 24 | $5.5B | $11.4B | ||
| Q3 24 | $8.0B | $10.6B | ||
| Q2 24 | $5.9B | $10.5B |
净利润BKNGTMO
| Q1 26 | — | $1.7B | ||
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.8B | ||
| Q3 24 | — | $1.6B | ||
| Q2 24 | — | $1.5B |
营业利润率BKNGTMO
| Q1 26 | — | 16.9% | ||
| Q4 25 | 32.0% | 18.5% | ||
| Q3 25 | 38.7% | 17.5% | ||
| Q2 25 | 33.1% | 16.9% | ||
| Q1 25 | 22.3% | 16.6% | ||
| Q4 24 | 31.6% | 17.7% | ||
| Q3 24 | 39.8% | 17.3% | ||
| Q2 24 | 31.7% | 17.3% |
净利率BKNGTMO
| Q1 26 | — | 15.0% | ||
| Q4 25 | — | 16.1% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | — | 14.9% | ||
| Q1 25 | — | 14.6% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | — | 15.4% | ||
| Q2 24 | — | 14.7% |
每股收益（稀释后）BKNGTMO
| Q1 26 | — | $4.43 | ||
| Q4 25 | $43.66 | $5.21 | ||
| Q3 25 | $84.41 | $4.27 | ||
| Q2 25 | $27.43 | $4.28 | ||
| Q1 25 | $10.07 | $3.98 | ||
| Q4 24 | $31.60 | $4.78 | ||
| Q3 24 | $74.34 | $4.25 | ||
| Q2 24 | $44.38 | $4.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $17.2B | $3.3B |
| 总债务越低越好 | $18.7B | — |
| 股东权益账面价值 | $-5.6B | $51.9B |
| 总资产 | $29.3B | $113.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BKNGTMO
| Q1 26 | — | $3.3B | ||
| Q4 25 | $17.2B | $10.1B | ||
| Q3 25 | $16.5B | $3.5B | ||
| Q2 25 | $17.6B | $6.4B | ||
| Q1 25 | $15.6B | $5.9B | ||
| Q4 24 | $16.2B | $5.6B | ||
| Q3 24 | $15.8B | $6.6B | ||
| Q2 24 | $16.3B | $8.8B |
总债务BKNGTMO
| Q1 26 | — | — | ||
| Q4 25 | $18.7B | $35.9B | ||
| Q3 25 | $17.0B | $31.9B | ||
| Q2 25 | $18.5B | $33.0B | ||
| Q1 25 | $16.0B | $31.4B | ||
| Q4 24 | $16.6B | $29.1B | ||
| Q3 24 | $16.2B | $31.2B | ||
| Q2 24 | $16.8B | $30.3B |
股东权益BKNGTMO
| Q1 26 | — | $51.9B | ||
| Q4 25 | $-5.6B | $53.4B | ||
| Q3 25 | $-4.7B | $51.0B | ||
| Q2 25 | $-6.7B | $50.5B | ||
| Q1 25 | $-6.1B | $49.4B | ||
| Q4 24 | $-4.0B | $49.6B | ||
| Q3 24 | $-3.7B | $49.0B | ||
| Q2 24 | $-4.3B | $47.4B |
总资产BKNGTMO
| Q1 26 | — | $113.3B | ||
| Q4 25 | $29.3B | $110.3B | ||
| Q3 25 | $28.8B | $103.0B | ||
| Q2 25 | $30.7B | $101.2B | ||
| Q1 25 | $27.2B | $99.0B | ||
| Q4 24 | $27.7B | $97.3B | ||
| Q3 24 | $28.0B | $100.4B | ||
| Q2 24 | $28.5B | $98.5B |
负债/权益比BKNGTMO
| Q1 26 | — | — | ||
| Q4 25 | — | 0.67× | ||
| Q3 25 | — | 0.62× | ||
| Q2 25 | — | 0.65× | ||
| Q1 25 | — | 0.64× | ||
| Q4 24 | — | 0.59× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.64× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.5B | $1.2B |
| 自由现金流经营现金流 - 资本支出 | $1.4B | $825.0M |
| 自由现金流率自由现金流/营收 | 22.3% | 7.5% |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | — | 0.72× |
| 过去12个月自由现金流最近4个季度 | $9.1B | $6.8B |
8季度趋势，按日历期对齐
经营现金流BKNGTMO
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.5B | $3.5B | ||
| Q3 25 | $1.4B | $2.2B | ||
| Q2 25 | $3.2B | $1.4B | ||
| Q1 25 | $3.3B | $723.0M | ||
| Q4 24 | $721.0M | $3.3B | ||
| Q3 24 | $2.4B | $2.2B | ||
| Q2 24 | $2.5B | $2.0B |
自由现金流BKNGTMO
| Q1 26 | — | $825.0M | ||
| Q4 25 | $1.4B | $3.0B | ||
| Q3 25 | $1.4B | $1.8B | ||
| Q2 25 | $3.1B | $1.1B | ||
| Q1 25 | $3.2B | $361.0M | ||
| Q4 24 | $645.0M | $2.8B | ||
| Q3 24 | $2.3B | $1.9B | ||
| Q2 24 | $2.4B | $1.7B |
自由现金流率BKNGTMO
| Q1 26 | — | 7.5% | ||
| Q4 25 | 22.3% | 24.5% | ||
| Q3 25 | 15.2% | 16.5% | ||
| Q2 25 | 46.1% | 10.2% | ||
| Q1 25 | 66.4% | 3.5% | ||
| Q4 24 | 11.8% | 24.7% | ||
| Q3 24 | 28.7% | 17.9% | ||
| Q2 24 | 40.6% | 15.7% |
资本支出强度BKNGTMO
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 3.8% | ||
| Q3 25 | 0.7% | 3.6% | ||
| Q2 25 | 0.9% | 2.7% | ||
| Q1 25 | 2.5% | 3.5% | ||
| Q4 24 | 1.4% | 4.2% | ||
| Q3 24 | 1.0% | 2.6% | ||
| Q2 24 | 2.5% | 2.9% |
现金转化率BKNGTMO
| Q1 26 | — | 0.72× | ||
| Q4 25 | — | 1.75× | ||
| Q3 25 | — | 1.39× | ||
| Q2 25 | — | 0.87× | ||
| Q1 25 | — | 0.48× | ||
| Q4 24 | — | 1.80× | ||
| Q3 24 | — | 1.33× | ||
| Q2 24 | — | 1.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BKNG
| Merchant Revenue | $4.2B | 67% |
| Agency Revenue | $1.8B | 28% |
| Advertisingandotherrevenues | $309.0M | 5% |
TMO
| Laboratory Products and Biopharma Services | $6.0B | 55% |
| Life Sciences Solutions | $2.6B | 24% |
| Analytical Instruments | $1.7B | 16% |
| Specialty Diagnostics | $1.1B | 10% |
